Pavan Cheruvu Named CEO Of Axovant Sciences
CEO, Axovant Gene Therapies
Pavan Cheruvu is the child of immigrants from India
Fellowship awarded to support work towards an MD in Medicine at Harvard University
Pavan Cheruvu, MD, is the President and CEO of Axovant Gene Therapies, a publicly traded biotechnology company focused on the development of gene therapies for neurodegenerative disorders, including Parkinson's disease and rare pediatric diseases.
A board-certified physician, Pavan completed his residency in internal medicine at Johns Hopkins Hospital and fellowship in cardiovascular medicine at the University of California, San Francisco. He previously worked as a management consultant at McKinsey & Company, where he focused on organizational and R&D strategy while serving a variety of clients, including large- and mid-cap biopharmaceutical firms. Over the course of his career, Pavan has worked with multiple biotechnology and medical device companies with focus areas spanning neurology, oncology, women's health and cardiology. Prior to his roles in academia and industry, he served as a policy intern at the Office of Science and Technology Policy (OSTP) at the White House.
Pavan graduated summa cum laude from Duke University with dual B.S.E. degrees in biomedical and electrical engineering, graduated with a master's degree in Computer Science from Oxford University as a Rhodes Scholar, and obtained his medical degree in a joint program between Harvard Medical School and the Massachusetts Institute of Technology (M.I.T.).
Pavan was born in the US to parents who emigrated from South India and are naturalized US citizens. He currently lives with his wife Deepu Madduri, MD, an oncologist and clinical investigator at Mt. Sinai Hospital, and their daughter in New York City.
Two Paul & Daisy Soros Fellows are behind the largest biotech IPO in history—Vivek Ramaswamy (2011 Fellow), the founder and CEO of Roivant Sciences, and Pavan Cheruvu (2004 Fellow), the chief of staff at Roivant Sciences.Read More